Microvast Holdings announces departure of chief financial officer
SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $1.1 billion market cap biotech company with a robust current ratio of 3.72, reported selling shares worth $48,029, according to a recent SEC filing. The transactions took place on February 4 and 5, 2025, involving a total of 4,000 shares of common stock. The sale prices ranged from $11.62 to $12.84 per share.
The sales were conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks, thereby avoiding concerns about insider trading. Following these transactions, Ma Songjiang, through indirect ownership by a spouse, holds 2,883,138 shares of Gyre Therapeutics.
Investors often scrutinize such transactions for insights into insider sentiment regarding the company’s future performance.
In other recent news, biotechnology firm Gyre Therapeutics has announced some key changes in its leadership. The company has appointed Ping Zhang as the lead independent director of its Board of Directors. Zhang, who has a strong financial background, will also serve on the Nominating and Corporate Governance Committee. Concurrently, there have been changes at Gyre Pharmaceuticals, an indirectly owned subsidiary of Gyre Therapeutics, with Songjiang Ma taking over as Chairman following Ying Luo’s decision to step down.
Zhang’s impressive experience includes his current position as a Managing Partner at String Capital Management and previous roles at AEON Life Insurance (NSE:LIFI) Company and Japan Asia Investment Co. He also holds a B.S. from Fudan University and an M.B.A. from the University of Chicago Booth School of Business.
These are recent developments that also highlight the company’s ongoing efforts. Gyre Therapeutics is currently focused on the development and commercialization of its drug F351 (Hydronidone) for MASH-associated fibrosis in the U.S. Meanwhile, Gyre Pharmaceuticals is advancing its pipeline in the People’s Republic of China, including clinical trials for F351 and the commercialization of ETUARY® (Pirfenidone capsule), a leading treatment for idiopathic pulmonary fibrosis in the PRC, which reported 2023 net sales of $112.1 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.